Compare AbbVie Inc (ABBV) vs Stryker Corporation (SYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Stryker Corporation — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while Stryker Corporation trades at $329.6 (market cap $126.41B). The key difference: AbbVie Inc is far larger — about 3.6× Stryker Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SYK | |
|---|---|---|
Market Cap | $449.91B | $126.41B |
Sector | Health | Technology |
52-Week High | $261.07 | $403.53 |
52-Week Low | $184.85 | $282.58 |
Enterprise Value | $513.38B | $138.17B |
Dividend Yield | 2.72% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Stryker (SYK) trades at $324.73, down 0.55% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 2025 revenue of $25.12B, net income of $3.25B, and consistent earnings beats in recent quarters despite a Q1 2026 miss. Analyst consensus remains strongly positive with 72% buy ratings and a $385.30 price target, representing 19% upside potential. Recent developments include new product launches and a strategic acquisition of Amplitude Vascular Systems.
SYK presents a compelling investment case with robust profitability (63.83% gross margin, 15.2% ROE) and strong institutional support. Key risks include cybersecurity incidents impacting operations and premium valuation metrics (P/E 37.58). The stock's current position near pivot point support at $323 suggests potential for recovery toward resistance at $329, supported by positive technical indicators and strong analyst conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
